Response rates to second-line STS therapies, including pazopanib, are typically <10% with median PFS <5 months, underscoring demand for predictive biomarkers. Transcriptomic profiling of 11 paired pre ...
Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results